|05th December,2018||11:00 am-12:30 pm||Track 3|
Investment in immunotherapy in 2018 is still attractive and sought out; what is its growth potential after several years of being an investment blockbuster? What have been the 2018 investment successes in immunotherapy? Will immunotherapy disrupt the oncology market? Are we at the growth, maturity, or saturation stage when we talk about investing in immunotherapy?
Juan Garcia - BioSeed Capital
Bram Vanparys - MS Ventures